FIVE PRIME THERAPEUTICS INC's ticker is FPRX and the CUSIP is 33830X104. A total of 88 filers reported holding FIVE PRIME THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.90 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $100,233,000 | +716.6% | 2,660,822 | +268.7% | 2.19% | +741.2% |
Q4 2020 | $12,275,000 | +862.0% | 721,633 | +165.7% | 0.26% | +712.5% |
Q3 2020 | $1,276,000 | -48.6% | 271,585 | -33.2% | 0.03% | -52.9% |
Q2 2020 | $2,481,000 | +173.2% | 406,729 | +1.7% | 0.07% | +78.9% |
Q1 2020 | $908,000 | -50.5% | 400,000 | 0.0% | 0.04% | -34.5% |
Q4 2019 | $1,836,000 | -38.9% | 400,000 | -48.4% | 0.06% | -51.7% |
Q3 2019 | $3,003,000 | -5.3% | 775,000 | +47.3% | 0.12% | +4.3% |
Q2 2019 | $3,172,000 | -53.1% | 526,100 | +4.2% | 0.12% | -55.9% |
Q1 2019 | $6,767,000 | +44.1% | 505,000 | 0.0% | 0.26% | +17.6% |
Q4 2018 | $4,697,000 | -43.6% | 505,000 | -15.6% | 0.22% | -26.2% |
Q3 2018 | $8,324,000 | -11.2% | 598,000 | +0.8% | 0.30% | -16.6% |
Q2 2018 | $9,375,000 | -6.8% | 593,000 | +1.3% | 0.36% | -15.9% |
Q1 2018 | $10,059,000 | +8.0% | 585,500 | +37.8% | 0.43% | +1.4% |
Q4 2017 | $9,316,000 | +4.6% | 425,000 | +95.2% | 0.42% | +2.9% |
Q3 2017 | $8,906,000 | +50.1% | 217,700 | +10.5% | 0.41% | +37.0% |
Q2 2017 | $5,932,000 | -0.6% | 197,000 | +19.4% | 0.30% | -12.8% |
Q1 2017 | $5,965,000 | -27.4% | 165,000 | +0.6% | 0.34% | -37.5% |
Q4 2016 | $8,218,000 | -5.8% | 164,000 | -1.4% | 0.55% | +0.5% |
Q3 2016 | $8,726,000 | +37.9% | 166,250 | +8.7% | 0.55% | +16.9% |
Q2 2016 | $6,327,000 | +7.8% | 153,000 | +5.9% | 0.47% | -4.9% |
Q1 2016 | $5,871,000 | +4.8% | 144,500 | +7.0% | 0.49% | +15.8% |
Q4 2015 | $5,603,000 | +203.4% | 135,000 | +12.5% | 0.42% | +183.3% |
Q3 2015 | $1,847,000 | -38.0% | 120,000 | 0.0% | 0.15% | -31.2% |
Q2 2015 | $2,981,000 | -4.1% | 120,000 | -11.8% | 0.22% | -25.1% |
Q1 2015 | $3,108,000 | -4.1% | 136,000 | +13.3% | 0.29% | -23.2% |
Q4 2014 | $3,240,000 | +140.2% | 120,000 | +4.3% | 0.38% | +81.3% |
Q3 2014 | $1,349,000 | -30.6% | 115,000 | -8.0% | 0.21% | -40.1% |
Q2 2014 | $1,944,000 | -43.5% | 125,000 | -28.6% | 0.35% | -56.0% |
Q1 2014 | $3,441,000 | – | 175,000 | – | 0.79% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Eventide Asset Management | 601,000 | $24,587,000 | 1.39% |
HealthCor Management, L.P. | 1,010,930 | $41,357,000 | 1.39% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 86,500 | $3,535,000 | 1.38% |
PURA VIDA INVESTMENTS, LLC | 75,000 | $3,068,000 | 0.90% |
BB BIOTECH AG | 777,500 | $31,808,000 | 0.88% |
AWM Investment Company, Inc. | 100,000 | $4,091,000 | 0.71% |
Granite Point Capital Management, L.P. | 50,000 | $2,046,000 | 0.43% |
Rock Springs Capital Management LP | 217,700 | $8,906,000 | 0.41% |
Crestline Management, LP | 50,919 | $2,083,000 | 0.29% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,432,700 | $99,522,000 | 0.24% |